In vitro and in vivo comparative study of a novel 68Ga-labeled PSMA-targeted inhibitor and 68Ga-PSMA-11

Abstract 68Ga-radiolabeled small molecules that specifically target prostate-specific membrane antigen (PSMA) have been extensively investigated, and some of these tracers have been used in the diagnosis of prostate cancer via 68Ga-positron emission tomography (68Ga-PET). Nevertheless, current 68Ga-...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Huanyu Chen, Ping Cai, Yue Feng, Zhanliang Sun, Yinwen Wang, Yue Chen, Wei Zhang, Nan Liu, Zhijun Zhou
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d8390b3ca8f8484c8850c936c95a4d06
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d8390b3ca8f8484c8850c936c95a4d06
record_format	dspace
spelling	oai:doaj.org-article:d8390b3ca8f8484c8850c936c95a4d062021-12-02T19:16:46ZIn vitro and in vivo comparative study of a novel 68Ga-labeled PSMA-targeted inhibitor and 68Ga-PSMA-1110.1038/s41598-021-98555-y2045-2322https://doaj.org/article/d8390b3ca8f8484c8850c936c95a4d062021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-98555-yhttps://doaj.org/toc/2045-2322Abstract 68Ga-radiolabeled small molecules that specifically target prostate-specific membrane antigen (PSMA) have been extensively investigated, and some of these tracers have been used in the diagnosis of prostate cancer via 68Ga-positron emission tomography (68Ga-PET). Nevertheless, current 68Ga-labeled radiotracers show only fair detection rates for metastatic prostate cancer lesions, especially those with lower levels of prostate specific antigen (PSA), which often occurs in the biochemical recurrence of prostate cancer. The goal of this study was to design and synthesize a new PSMA-targeted radiotracer, 68Ga-SC691, with high affinity for prostate cancer cells and excellent pharmacokinetics. To this end, structural optimization was carried out on the bifunctional group, target motif, and linker while the high affinity targeting scaffold remained. To explore its potential in the clinic, a comparative study was further performed in vitro and in vivo between 68Ga-SC691 and 68Ga-PSMA-11, a clinically approved tracer for PSMA-positive prostate cancer. SC691 was radiolabeled to provide 68Ga-SC691 in 99% radiolabeling yield under mild conditions. High uptake and a high internalization ratio into LNCaP cells were observed in in vitro studies. In vivo studies showed that 68Ga-SC691 had favorable biodistribution properties and could specifically accumulate on PSMA-positive LNCaP xenografts visualized by micro-PET/CT. This radiotracer showed excellent PET imaging quality and comparable, if not higher, uptake in LNCaP xenografts than 68Ga-PSMA-11.Huanyu ChenPing CaiYue FengZhanliang SunYinwen WangYue ChenWei ZhangNan LiuZhijun ZhouNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Huanyu Chen Ping Cai Yue Feng Zhanliang Sun Yinwen Wang Yue Chen Wei Zhang Nan Liu Zhijun Zhou In vitro and in vivo comparative study of a novel 68Ga-labeled PSMA-targeted inhibitor and 68Ga-PSMA-11
description	Abstract 68Ga-radiolabeled small molecules that specifically target prostate-specific membrane antigen (PSMA) have been extensively investigated, and some of these tracers have been used in the diagnosis of prostate cancer via 68Ga-positron emission tomography (68Ga-PET). Nevertheless, current 68Ga-labeled radiotracers show only fair detection rates for metastatic prostate cancer lesions, especially those with lower levels of prostate specific antigen (PSA), which often occurs in the biochemical recurrence of prostate cancer. The goal of this study was to design and synthesize a new PSMA-targeted radiotracer, 68Ga-SC691, with high affinity for prostate cancer cells and excellent pharmacokinetics. To this end, structural optimization was carried out on the bifunctional group, target motif, and linker while the high affinity targeting scaffold remained. To explore its potential in the clinic, a comparative study was further performed in vitro and in vivo between 68Ga-SC691 and 68Ga-PSMA-11, a clinically approved tracer for PSMA-positive prostate cancer. SC691 was radiolabeled to provide 68Ga-SC691 in 99% radiolabeling yield under mild conditions. High uptake and a high internalization ratio into LNCaP cells were observed in in vitro studies. In vivo studies showed that 68Ga-SC691 had favorable biodistribution properties and could specifically accumulate on PSMA-positive LNCaP xenografts visualized by micro-PET/CT. This radiotracer showed excellent PET imaging quality and comparable, if not higher, uptake in LNCaP xenografts than 68Ga-PSMA-11.
format	article
author	Huanyu Chen Ping Cai Yue Feng Zhanliang Sun Yinwen Wang Yue Chen Wei Zhang Nan Liu Zhijun Zhou
author_facet	Huanyu Chen Ping Cai Yue Feng Zhanliang Sun Yinwen Wang Yue Chen Wei Zhang Nan Liu Zhijun Zhou
author_sort	Huanyu Chen
title	In vitro and in vivo comparative study of a novel 68Ga-labeled PSMA-targeted inhibitor and 68Ga-PSMA-11
title_short	In vitro and in vivo comparative study of a novel 68Ga-labeled PSMA-targeted inhibitor and 68Ga-PSMA-11
title_full	In vitro and in vivo comparative study of a novel 68Ga-labeled PSMA-targeted inhibitor and 68Ga-PSMA-11
title_fullStr	In vitro and in vivo comparative study of a novel 68Ga-labeled PSMA-targeted inhibitor and 68Ga-PSMA-11
title_full_unstemmed	In vitro and in vivo comparative study of a novel 68Ga-labeled PSMA-targeted inhibitor and 68Ga-PSMA-11
title_sort	in vitro and in vivo comparative study of a novel 68ga-labeled psma-targeted inhibitor and 68ga-psma-11
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/d8390b3ca8f8484c8850c936c95a4d06
work_keys_str_mv	AT huanyuchen invitroandinvivocomparativestudyofanovel68galabeledpsmatargetedinhibitorand68gapsma11 AT pingcai invitroandinvivocomparativestudyofanovel68galabeledpsmatargetedinhibitorand68gapsma11 AT yuefeng invitroandinvivocomparativestudyofanovel68galabeledpsmatargetedinhibitorand68gapsma11 AT zhanliangsun invitroandinvivocomparativestudyofanovel68galabeledpsmatargetedinhibitorand68gapsma11 AT yinwenwang invitroandinvivocomparativestudyofanovel68galabeledpsmatargetedinhibitorand68gapsma11 AT yuechen invitroandinvivocomparativestudyofanovel68galabeledpsmatargetedinhibitorand68gapsma11 AT weizhang invitroandinvivocomparativestudyofanovel68galabeledpsmatargetedinhibitorand68gapsma11 AT nanliu invitroandinvivocomparativestudyofanovel68galabeledpsmatargetedinhibitorand68gapsma11 AT zhijunzhou invitroandinvivocomparativestudyofanovel68galabeledpsmatargetedinhibitorand68gapsma11
_version_	1718376941434699776

In vitro and in vivo comparative study of a novel 68Ga-labeled PSMA-targeted inhibitor and 68Ga-PSMA-11

Ejemplares similares